Syndax Pharmaceuticals reported strong Q2 2026 results with total revenue of $73 million, up 92% year-over-year, driven by Revuforj net revenue of $54.7 million and Niktimvo net revenue of $60.3 million. The company highlighted ongoing clinical trials and pipeline expansion, including new drug candidates for lung cancer and myelofibrosis. Upcoming data releases from Phase 2 trials of axatilimab in IPF and frontline cGVHD are expected in Q4 2026, supporting future growth prospects. Syndax also expects to reach profitability with its current cash and revenue streams.
With U.S. crude oil prices above $100 a barrel, investors are shifting focus to smaller companies with promising technologies and upcoming catalysts. Kraig Biocraft Laboratories shipped its first commercial spider silk yarn order, moving toward scala...
FS Bancorp, Inc. has appointed Matthew D. Mullet as a director on the boards of both the company and its bank, 1st Security Bank of Washington, effective October 22, 2026. Mullet, who has been President since 2024 and CEO since 2025-2026, brings exte...
The global protein ingredients market, valued at $42.3 billion in 2025, is projected to grow to $65 billion by 2032 with a CAGR of 6.3%. Growth is driven by rising consumer demand for health-focused, protein-enriched foods, sports nutrition, and sust...
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
